A prospective, randomized, double-blinded, multicenter, active-controlled trial of efficacy and safety of fexuprazan compared to esomeprazole in patients with laryngopharyngeal reflux disease (LPRD)
Latest Information Update: 19 Nov 2024
Price :
$35 *
At a glance
- Drugs Fexuprazan (Primary) ; Esomeprazole
- Indications Laryngopharyngeal reflux
- Focus Adverse reactions; Therapeutic Use
- 19 Nov 2024 New trial record
- 01 Nov 2024 Results assessing efficacy and safety of fexuprazan compared to esomeprazole in patients with Laryngopharyngeal reflux disease, published in the European Archives of Oto-Rhino-Laryngology.